Drug Safety

, Volume 22, Issue 3, pp 179–190 | Cite as

A Risk-Benefit Analysis of Methadone Maintenance Treatment

Review Article

Abstract

Methadone maintenance treatment for heroin (diamorphine) addiction has been extensively researched. There is consistent evidence that while in treatment, heroin addicts are at a lower risk of death, are less involved in crime, and feel and function better than while using heroin. Despite the research evidence supporting methadone treatment, there remains widespread public scepticism about this form of treatment. This scepticism is frequently expressed in terms of the perceived risks of methadone treatment. The perceived risk that methadone treatment may maintain people in an addicted lifestyle is not supported by research literature. The risks of treatment include an increased risk of death during induction into treatment, and risks of diversion of drugs to the black market. For some patients, adverse effects of methadone pose a problem and the availability of new pharmacotherapies may provide useful options for these patients. Risks can be reduced and benefits increased by directing greater attention to the quality of treatment.

References

  1. 1.
    D’Aunno T, Vaughan TE. Variations in methadone treatment practices: results from a national study. JAMA 1992; 267: 253–8PubMedCrossRefGoogle Scholar
  2. 2.
    Neale J. Drug users’ views on prescribed methadone. Drugs Educ Prev Pol 1998; 5: 33–45Google Scholar
  3. 3.
    Dole VP, Nyswander M. Methadone maintenance: a ten year perspective. JAMA 1976; 235: 2117–9PubMedCrossRefGoogle Scholar
  4. 4.
    Marks J. Deaths from methadone and heroin [letter]. Lancet 1994; 343: 976PubMedCrossRefGoogle Scholar
  5. 5.
    McCarthy JH. More people die from methadone misuse than from heroin misuse [letter]. BMJ 1997; 315: 603PubMedCrossRefGoogle Scholar
  6. 6.
    Ausubel DP. Methadone maintenance treatment: the other side of the coin. Int J Addict 1983; 18 (6): 851–62PubMedGoogle Scholar
  7. 7.
    Gearing FR, Schweitzer MD. An epidemiologic evaluation of long–term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974; 100: 101–12PubMedGoogle Scholar
  8. 8.
    Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment.Acta Psychiatr Scand 1990; 82 (3): 223–7PubMedCrossRefGoogle Scholar
  9. 9.
    Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality: a case control within a cohort of intravenous drug users. Int J Epidemiol 1993; 22: 273–7PubMedCrossRefGoogle Scholar
  10. 10.
    Zanis DA, Woody GE. One–year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998: 52 (3): 257–60PubMedCrossRefGoogle Scholar
  11. 11.
    Joseph H, Appel P, Schmudler J. Deaths during and after discharge from methadone maintenance treatment. Outcome study report; no. 18. New York (NY): New York State Division of Substance Abuse Services, 1981.Google Scholar
  12. 12.
    Drummer OH, Opeskin K, Syrjanen M, et al. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol 1992; 13: 346–50PubMedCrossRefGoogle Scholar
  13. 13.
    Gardner R. Methadone misuse and death by overdosage. Br J Addict 1970; 65 (2): 113–8CrossRefGoogle Scholar
  14. 14.
    Harding–Pink D.Methadone: one person’s maintenance dose is another’s poison [letter]. Lancet 1993; 341: 665–6PubMedCrossRefGoogle Scholar
  15. 15.
    Caplehorn JR, Dalton SY, Haldar F, et al. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse 1996; 31: 177–96PubMedCrossRefGoogle Scholar
  16. 16.
    Barrett DH, Luk AJ, Parrish RG, et al. An investigation ofmedical examiner cases in which methadone was detected, Harris County, Texas, 1987–1992. J Forensic Sci 1996; 41: 442–8PubMedGoogle Scholar
  17. 17.
    Zador DA, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia, 1990–1995. Addiction. In pressGoogle Scholar
  18. 18.
    Sunjic S, Zador DA. Methadone related deaths in New South Wales, July 1990–December 1995. Drug Alcohol Rev. In pressGoogle Scholar
  19. 19.
    Darke S, Ross J, Hall W. The injection of methadone syrup in Sydney, Australia. Sydney: National Drug and Alcohol Research Centre, 1995. (Technical report no. 23)Google Scholar
  20. 20.
    Zador D, Sunjic S,Darke S.Heroin–related deaths in NewSouth Wales, 1992: toxicological findings and circumstances. Med J Aust 1996; 164: 204–7PubMedGoogle Scholar
  21. 21.
    HallW, LenskyM, Degenhardt L. Trends inmethadone–related deaths in the UK and Australia, 1985–1995. Sydney (NSW): National Drug and Alcohol Research Centre, 1998. (NDARC Technical report no. 69)Google Scholar
  22. 22.
    Clark JC, Milroy CM, Forrest ARW. Deaths from methadone use. J Clin Forensic Med 1995; 2: 143–4PubMedCrossRefGoogle Scholar
  23. 23.
    Spunt B, Hunt D, Lipton D, et al. Methadone diversion: a new look. J Drug Issues 1986; 18: 569–83Google Scholar
  24. 24.
    Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170: 104–9PubMedGoogle Scholar
  25. 25.
    Dole VP, Robinson JW, Orraca J, et al.Methadone treatment of randomly selected criminal addicts. N Engl JMed 1969; 280: 1372–5CrossRefGoogle Scholar
  26. 26.
    Newman RG, Whitehill WB. Double–blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; II (8141): 485–8CrossRefGoogle Scholar
  27. 27.
    Gunne LM, Grodbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981; 7 (3): 249–56PubMedCrossRefGoogle Scholar
  28. 28.
    Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadonemaintenance clinic.AmJ Public Health 1991; 81: 1185–91Google Scholar
  29. 29.
    Strain EC, Stitzer ML, Liebson IA. et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-report, urinalysis, and addiction severity index. J Psychopharmacol 1996; 16 (1): 58–67CrossRefGoogle Scholar
  30. 30.
    Hubbard RL, Marsden ME, Rachel JV, et al. Drug abuse treatment: a national study of effectiveness. Chapel Hill (NC): University of North Carolina Press, 1989Google Scholar
  31. 31.
    Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services and outcomes. New York (NY): Springer Verlag, 1991CrossRefGoogle Scholar
  32. 32.
    HargreavesWA.Methadone dose and duration for maintenance treatment. In: Cooper JR, Altman F, Brown BS, et al, editors. Research on the treatment of narcotic addiction. Rockville (MD): National Institute on Drug Abuse, 1983: 19–80Google Scholar
  33. 33.
    McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA1993; 269 (15): 1953–9PubMedCrossRefGoogle Scholar
  34. 34.
    Metger DS, Woody GE, McLellan AT, et al. Human Immunodeficiency Virus seroconversion among intravenous drug users in and out of treatment: an 18–month prospective follow–up. J Acquir Immune Defic Syndr 1993; 6: 1049–55Google Scholar
  35. 35.
    Moss AR, Vranzian K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco 1985–1990. AIDS 1994; 8: 223–31PubMedCrossRefGoogle Scholar
  36. 36.
    Van Ameijden EJC, van den Hoek AAR, Couthino RA. Injecting risk behaviour among injecting drug users in Amsterdam, 1986–1992, and its relationship to AIDS prevention programs. Am J Public Health 1994; 84: 275–81PubMedCrossRefGoogle Scholar
  37. 37.
    Anglin D, McGlothlin WH. Outcome of narcotic addiction treatment in California. In: Timms FM, Luford JP, editors. Drug abuse treatment evaluation: strategies, progress and prospect [NIDA Research Monograph 51]. Rockville (MD): National Institute on Drug Abuse, 1984: 106–28Google Scholar
  38. 38.
    Bell J, Ward J, Mattick RP, et al. An evaluation of private methadone clinics. Canberra: Australian Government Publishing Service; 1995. (National Drug Strategy Research report no. 4)Google Scholar
  39. 39.
    Milby JB. Methadone maintenance to abstinence: how many make it? J Nerv Ment Dis 1988; 176: 409–22PubMedCrossRefGoogle Scholar
  40. 40.
    Bell J, Mattick RP, Chan J, et al. Methadone maintenance and drug related crime. J Subst Abuse Treat 1997; 9: 15–25CrossRefGoogle Scholar
  41. 41.
    Kreek MJ. Medical safety and side–effects of methadone in tolerant individuals. J Psychoactive Drugs 1991; 23: 232–8Google Scholar
  42. 42.
    Reno RR, Aiken LS. Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict 1993; 28 (3): 211–32PubMedGoogle Scholar
  43. 43.
    Torrens M, San L, Martinez A, et al. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997; 92 (6): 707–16PubMedCrossRefGoogle Scholar
  44. 44.
    Martin WR, Jasinski JR, Haertzen CA, et al. Methadone: a reevaluation. Arch Gen Psychiatry 1973; 28: 286–95PubMedCrossRefGoogle Scholar
  45. 45.
    Angle BP, Hadley TR, Odim U. The heroin addict’s view of personal change during methadone maintenance treatment. Br J Addict 1979; 74: 208–10CrossRefGoogle Scholar
  46. 46.
    Langrod J, Lowinson J, Ruiz P. Methadone treatment and physical complaints: a clinical analysis. Int J Addict 1981; 16 (5): 947–52PubMedGoogle Scholar
  47. 47.
    Dyer KR, White JM. Patterns of symptoms complaints in methadone maintenance patients. Addiction 1997; 92: 1445–55PubMedCrossRefGoogle Scholar
  48. 48.
    Sheedy JJ.Methadone and caries: case reports. AustDent 1996; 41 (6): 367–9Google Scholar
  49. 49.
    Judson BA, Goldstein A. Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers. Drug Alcohol Depend 1982; 10 (2–3): 269–82PubMedCrossRefGoogle Scholar
  50. 50.
    Kerr B, Hill H, Coda B, et al. Concentration–related effects of morphine on cognition and motor control in human subjects. Neuropsychopharmacology 1991; 5: 157–66PubMedGoogle Scholar
  51. 51.
    Zacny JP. Areview of the effects of opiates on psychomotor and cognitive functioning in humans. Exp Clin Psychopharm 1995; 3: 432–66CrossRefGoogle Scholar
  52. 52.
    Johnson RE, Chutuape MA, Strain EC, et al. First randomized controlled trial (RCT) of methadone (M), Levomethadyl acetate (LAAM) and buprenorphine (BUP) in opioid dependence treatment [abstract]. Clin Pharmacol Ther 1999; 65 (2): 145CrossRefGoogle Scholar
  53. 53.
    Hunt DA, Lipton DS, Goldsmith DS, et al. It takes your heart: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict 1985–86; 20 (11–12): 1751–71Google Scholar
  54. 54.
    Maddux JF, Desmond DP. Ten–year follow–up after admission to methadone maintenance. Am J Drug Alcohol Abuse 1992; 18 (3): 289–303PubMedCrossRefGoogle Scholar
  55. 55.
    Maddux JF, Desmond DP. Methadone maintenance and recovery fromopioid dependence.AmJournalDrugAlcoholAbuse 1992; 18 (1): 63–74CrossRefGoogle Scholar
  56. 56.
    McGlothlin WH, Anglin MD. Long–term follow–up of clients of high– and low–dose methadone programs. Arch Gen Psychiatry 1981; 38: 1055–63PubMedCrossRefGoogle Scholar
  57. 57.
    Murphy S, Irwin J. Living with the dirty secret: problems of disclosure for methadone maintenance clients. J Psychoactive Drugs 1992; 24: 257–64PubMedCrossRefGoogle Scholar
  58. 58.
    Cooper JR. Ineffective use of psychoactive drugs: methadone treatment is no exception. JAMA 1992; 267 (2): 281–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.The Langton CentreSurry HillsAustralia
  2. 2.Drug and Alcohol DepartmentConcord HospitalConcordAustralia

Personalised recommendations